Is infliximab more effective than a placebo for fistula healing in patients with Crohn’s disease?


Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893.


To review of the evidence for the effectiveness of TNF-alpha blocking agents in the maintenance of remission in patients with Crohn’s disease.


Focused question

Literature review: Searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the IBD/FBD Review Group Specialized Trials Register for studies published 1966-2007.

Inclusion criteria: Randomized controlled trials involving patients > 18 years with Crohn’s disease who had a clinical response or clinical remission with a TNF-alpha blocking agent, or patients with Crohn’s disease in remission but unable to wean corticosteroids, who were then randomized to maintenance of remission with a TNF-alpha blocking agent or placebo

Validity criteria: randomization, allocation concealment, blinding, follow-up, intention-to-treat analysis

Assessments of studies: independent review by each of the two authors; resolution of disagreement by consensus of the two


Analysis 1.4 shows the risk ratio for fistula healing, comparing placebo to infliximab.

About Amy

Clinical Informationist at EUH Branch Library
This entry was posted in Diagnosis. Bookmark the permalink.